L Aarden

10.9k total citations · 3 hit papers
104 papers, 8.3k citations indexed

About

L Aarden is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, L Aarden has authored 104 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Immunology, 41 papers in Radiology, Nuclear Medicine and Imaging and 22 papers in Molecular Biology. Recurrent topics in L Aarden's work include Monoclonal and Polyclonal Antibodies Research (41 papers), T-cell and B-cell Immunology (29 papers) and Systemic Lupus Erythematosus Research (16 papers). L Aarden is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (41 papers), T-cell and B-cell Immunology (29 papers) and Systemic Lupus Erythematosus Research (16 papers). L Aarden collaborates with scholars based in Netherlands, United Kingdom and United States. L Aarden's co-authors include L C Boeije, E R de Groot, John Wijdenes, T. E. W. Feltkamp, R J Smeenk, SJ van Deventer, JW ten Cate, Gertjan Wolbink, A. J. G. Swaak and C. Erik Hack and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

L Aarden

104 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6

1989 650 citations L Aarden et al. Blood profile →
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways

1990 633 citations L Aarden et al. Blood profile →
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.

1995 585 citations L C Boeije, R J Smeenk et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L Aarden Netherlands	47	4.1k	1.8k	1.7k	1.7k	1.4k	104	8.3k
Lucien A. Aarden Netherlands	45	4.4k 1.1×	2.4k 1.3×	1.6k 1.0×	1.2k 0.7×	1.2k 0.8×	101	9.1k
John Wijdenes France	55	5.0k 1.2×	2.2k 1.3×	1.3k 0.8×	1.4k 0.8×	3.0k 2.1×	188	9.8k
Curtis B. Wilson United States	52	3.5k 0.9×	2.2k 1.2×	1.6k 1.0×	1.5k 0.9×	799 0.6×	154	10.2k
David A. Horwitz United States	57	7.5k 1.8×	1.4k 0.8×	1.1k 0.6×	2.1k 1.2×	1.5k 1.1×	129	10.6k
Paolo Casali United States	59	6.7k 1.6×	2.6k 1.5×	2.9k 1.7×	1.7k 1.0×	958 0.7×	184	11.1k
Claudia Mauri United Kingdom	49	9.2k 2.3×	2.0k 1.1×	986 0.6×	2.1k 1.2×	2.0k 1.4×	135	13.7k
Francesco Tedesco Italy	53	5.4k 1.3×	1.4k 0.8×	1.1k 0.6×	1.7k 1.0×	686 0.5×	190	9.3k
Joachim R. Kalden Germany	44	5.6k 1.4×	2.0k 1.1×	1.5k 0.9×	5.9k 3.5×	1.2k 0.8×	103	11.7k
Lennart Truedsson Sweden	49	4.3k 1.1×	1.1k 0.6×	806 0.5×	2.5k 1.5×	511 0.4×	186	7.6k
Brian L. Kotzin United States	59	8.5k 2.1×	1.7k 1.0×	2.3k 1.4×	3.8k 2.2×	1.4k 1.0×	175	13.5k

Countries citing papers authored by L Aarden

Since Specialization

Citations

This map shows the geographic impact of L Aarden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Aarden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Aarden more than expected).

Fields of papers citing papers by L Aarden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Aarden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Aarden. The network helps show where L Aarden may publish in the future.

Co-authorship network of co-authors of L Aarden

This figure shows the co-authorship network connecting the top 25 collaborators of L Aarden. A scholar is included among the top collaborators of L Aarden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Aarden. L Aarden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stephan, Frank, Ingrid Bulder, Alan E. Mast, et al.. (2012). Tissue factor pathway inhibitor is an inhibitor of factor VII‐activating protease. Journal of Thrombosis and Haemostasis. 10(6). 1165–1171. 14 indexed citations

Thurlings, Rogier M., Koen Vos, Daniëlle M. Gerlag, et al.. (2009). Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 69(2). 409–412. 89 indexed citations

Bartelds, G. M., Carla A. Wijbrandts, Michael T. Nurmohamed, et al.. (2009). Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Annals of the Rheumatic Diseases. 69(5). 817–821. 174 indexed citations

Vries, Mirjam K. de, Gertjan Wolbink, Steven O. Stapel, et al.. (2007). Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Annals of the Rheumatic Diseases. 66(9). 1252–1254. 113 indexed citations

Laine, Marja L., et al.. (2007). Activation of toll‐like receptors 2 and 4 by gram‐negative periodontal bacteria. Oral Microbiology and Immunology. 22(3). 145–151. 130 indexed citations

Laken, Conny J. van der, Alexandre E. Voskuyl, Jan C. Roos, et al.. (2006). Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Annals of the Rheumatic Diseases. 66(2). 253–256. 147 indexed citations

Nielen, M., A. R. van der Horst, D. van Schaardenburg, et al.. (2005). Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Annals of the Rheumatic Diseases. 64(8). 1199–1204. 147 indexed citations

Krijnen, Paul A.J., Saskia A.G.M. Cillessen, Alice Muller, et al.. (2005). Clusterin: a protective mediator for ischemic cardiomyocytes?. American Journal of Physiology-Heart and Circulatory Physiology. 289(5). H2193–H2202. 52 indexed citations

Bijl, Marc, P. C. Limburg, PE Spronk, et al.. (1998). Do Elevated Levels of Serum-Soluble Fas Contribute to the Persistence of Activated Lymphocytes in Systemic Lupus Erythematosus?. Journal of Autoimmunity. 11(5). 457–463. 26 indexed citations

10.

Kraan, Tineke C. T. M. van der Pouw, L C Boeije, A. J. Snijders, et al.. (1996). Regulation of IL‐12 Production by Human Monocytes and the Influence of Prostaglandin E₂. Annals of the New York Academy of Sciences. 795(1). 147–157. 30 indexed citations

11.

Jansen, PM, et al.. (1996). Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon- gamma. Blood. 87(12). 5144–5151. 70 indexed citations

12.

Hon, Floris D. de, Marc Ehlers, Stefan Rose‐John, et al.. (1994). Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.. The Journal of Experimental Medicine. 180(6). 2395–2400. 45 indexed citations

13.

Parren, Paul W.H.I., P A Warmerdam, L C Boeije, et al.. (1992). On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.. Journal of Clinical Investigation. 90(4). 1537–1546. 278 indexed citations

14.

Boer, Elizabeth C. de, Wim H. de Jong, P. A. Steerenberg, et al.. (1992). Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunology Immunotherapy. 34(5). 306–312. 162 indexed citations

15.

Parren, Paul W.H.I., Marlieke Geerts, L C Boeije, & L Aarden. (1991). Induction of T-cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies. Research in Immunology. 142(9). 749–763. 19 indexed citations

16.

Shalaby, M R, Jostein Halgunset, L Aarden, et al.. (1991). Cytokine-associated tissue injury and lethality in mice: A comparative study. Clinical Immunology and Immunopathology. 61(1). 69–82. 22 indexed citations

17.

Kooten, Cees van, M. H. van Oers, & L Aarden. (1990). Interleukin-6 enhances human Ig production, but not as a terminal differentiation factor for B lymphocytes. Research in Immunology. 141(4). 341–356. 8 indexed citations

18.

Löwik, Clemens W.G.M., Gabri van der Pluijm, Klaas Hoekman, et al.. (1989). Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis. Biochemical and Biophysical Research Communications. 162(3). 1546–1552. 316 indexed citations

19.

Swaak, A. J. G., Anthony van Rooyen, & L Aarden. (1989). Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatology International. 8(6). 263–268. 47 indexed citations

20.

Swaak, A. J. G., Anthony van Rooyen, EES Nieuwenhuis, & L Aarden. (1988). lnterleukin-6 (IL-6) in Synovial Fluid and Serum of Patients with Rheumatic Diseases. Scandinavian Journal of Rheumatology. 17(6). 469–474. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact